...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of endocrinology >Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats
【24h】

Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats

机译：大剂量苯扎贝特治疗预防血浆三酰甘油升高，消除了地塞米松短期治疗所致大鼠的胰岛素抵抗并减轻了葡萄糖耐量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. Fibrates are used as lipid-lowering drugs and are well tolerated as cotreatments when glucose metabolism disturbances are also present. Synthetic glucocorticoids (GCs) are diabetogenic drugs that cause dyslipidemia, dysglycemia, glucose intolerance, and insulin resistance when in excess. Thus, we aimed to describe the potential of bezafibrate in preventing or attenuating the adverse effects of GCs on glucose and lipid homeostasis. Methods. Male Wistar rats were treated with high-dose bezafibrate (300 mg/kg, body mass (b.m.)) daily for 28 consecutive days. In the last five days, the rats were also treated with dexamethasone (1 mg/kg, b.m.). Results. Dexamethasone treatment reduced the body mass gain and food intake, and bezafibrate treatment exerted no impact on these parameters. GC treatment caused an augmentation in fasting and fed glycemia, plasma triacylglycerol and nonesterified fatty acids, and insulinemia, and bezafibrate treatment completely prevented the elevation in plasma triacylglycerol and attenuated all other parameters. Insulin resistance and glucose intolerance induced by GC treatment were abolished and attenuated, respectively, by bezafibrate treatment. Conclusion. High-dose bezafibrate treatment prevents the increase in plasma triacylglycerol and the development of insulin resistance and attenuates glucose intolerance in rats caused by GC treatment, indicating the involvement of dyslipidemia in the GC-induced insulin resistance.
机译：目的。贝特类药物被用作降脂药物，当还存在葡萄糖代谢紊乱时，其作为辅助药物具有良好的耐受性。合成糖皮质激素（GCs）是一种致糖尿病药物，过量时会引起血脂异常，血糖异常，葡萄糖耐受不良和胰岛素抵抗。因此，我们旨在描述苯扎贝特在预防或减轻GC对葡萄糖和脂质体内稳态的不利影响方面的潜力。方法。雄性Wistar大鼠每天接受大剂量苯扎贝特（300μmg/ kg，体重（b.m.））治疗，连续28天。在最后五天，还用地塞米松（1μg/ kg，体重，b.m。）治疗了大鼠。结果。地塞米松治疗减少了体重增加和食物摄入，苯扎贝特治疗对这些参数没有影响。气相色谱治疗导致空腹和进食血糖，血浆三酰甘油和非酯化脂肪酸以及胰岛素血症的增加，苯扎贝特治疗完全阻止血浆三酰甘油升高，并减弱所有其他参数。通过苯扎贝特酸盐处理分别消除和减弱了由GC处理引起的胰岛素抵抗和葡萄糖耐受不良。结论。大剂量苯扎贝特治疗可防止血浆甘油三酯增加和胰岛素抵抗的发展，并减轻由GC治疗引起的大鼠的葡萄糖耐量下降，表明血脂异常与GC诱导的胰岛素抵抗有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号